NK-T-Cell Lymphoma, Extranodal
Conditions
Brief summary
A prospective, open-abel, phase 2 clinical study to investigate whether interim Positron Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the prognosis of localized nasal extranodal NK/T cell lymphoma (ENKTL) patients.
Detailed description
This study aims to evaluate the significance of mid-term PET and EBV DNA-directed therapy for localized nasal ENKTL. Patients receive 2 cycles of ESA (Pegaspargase, Etoposide, Dexamethasone) regimen, then according to the mid-term PET and EBV DNA results, patients are divided into three cohorts: 1) cohort A: patients with Deauville score 1-3 and EBV DNA negative receive sequential radiotherapy and 2 cycles of ESA regimen; 2) cohort B: patients with Deauville score 1-3 and EBV DNA positive receive sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase; 3) cohort C: patients with Deauville score 4-5 receive 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, then 2 cycles of PD-1 monoclonal antibody combined with pegaspargase.
Interventions
DRUG4 cycles of ESA regimen with sandwiched radiotherapy
Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
DRUG2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
DRUG2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
PD-1 monoclonal antibody, 200mg, i.v. d1
Sponsors
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically newly diagnosed extranodal NK/T cell lymphoma, nasal type (according to the WHO classification 2016); * No previous anti-lymphoma treatment; * Age ≥ 18 years old; * Ann Arbor stage I/II; * ECOG 0-2 score; * Patients with a life expectancy of at least 3 months; * At least one measurable / evaluable lesion from diagnostic biopsy to the beginning of treatment; * Sufficient bone marrow and liver and kidney function, namely: 1. Absolute neutrophil count (ANC)\> 1000 / μL, platelet count\> 50, 000 / μl, hemoglobin\> 9g/ dl; 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<3 times the upper limit of normal (ULN); Serum total bilirubin \<1. 5 times ULN (patients with Gilbert syndrome can be included); 3. Serum creatinine \<2 times ULN or creatinine clearance rate\> 50 ml/min. * Able to comply with the research procedures and cooperate in the implementation of the entire research process; * Written informed consent; * Women with fertility agree to take appropriate measures to avoid pregnancy during the treatment period until at least one year after the end of treatment; Men agree to maintain abstinence or use barrier contraception.
Exclusion criteria
* Diagnosed invasive NK cell leukemia and extranasal ENKTL; * Ann Arbor stage III/IV; * Pregnant or lactation; * Autoimmune diseases that require systemic treatment in the past 2 years (namely, antirheumatic drugs, hormones or immunosuppressants), including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome related vascular thrombosis, Wegener's granuloma, Sjogren's syndrome, Guillain Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis. The following cases are allowed to be included: autoimmune hypothyroidism or type I diabetes receiving stable treatment, hormone replacement treatment (such as thyroxine, insulin, or supplement of physiological hormone due to insufficient adrenal or pituitary gland) are not considered as systematic treatment and are allowed to be included. * Other invasive cancers that have not received curative treatment or are still receiving anti-cancer treatment (including hormone therapy for breast cancer or prostate cancer) in the past 3 years; * Pneumonia requiring steroid medication treatment (non-infectious); Or had clinical evidence of interstitial lung disease or active and non-infectious pneumonia; * Active infections that require systemic treatment; * Severe cardiovascular disease, or myocardial infarction, unstable arrhythmia, or unstable angina pectoris occurring 3 months ago; * Previous treatment with anti PD-1, anti PD-L1, or anti PD-L2 drugs; * HBsAg, HCV, or HIV positivity; HBV and HCV serological positivity is allowed, but DNA/RNA must be negative; * Live attenuated vaccine vaccination within 4 weeks before the treatment; patients are prohibited from receiving live attenuated vaccines during the study period, including influenza vaccines; * Central nervous system diseases; * Previous allogeneic tissue/solid organ transplantation; * Active tuberculosis; * Other concurrent uncontrollable medical conditions that may interfere the participation of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year progression-free survival rate | Baseline up to data cut-off (up to approximately 2 years) | Progression-free survival was defined as the time from the date of randomization until the date of the first disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year overall survival rate | Baseline up to data cut-off (up to approximately 2 years) | Overall survival was defined as the time from the date of randomization to the date of death from any cause. |
| 2-year PFS and OS rates in the subgroups of interim Deauville score 1-3 with EBV DNA negative, Deauville 1-3 with EBV DNA positive, and Deauville 4-5 | Baseline up to data cut-off (up to approximately 2 years) | PFS was progression-free survival; OS was overall survival. |
| Objective response rate | End of treatment (6-8 weeks after last cycle) | Percentage of participants with complete response and partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Complete response rate | End of treatment (6-8 weeks after last cycle) | Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Treatment-Related Adverse Events rate as assessed by CTCAE version 5.0 | From enrollment to study completion, a maximum of 3 years | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
| Changes of plasma EBV DNA load | From enrollment to study completion, a maximum of 3 years | Plasma EBV DNA load monitoring |
Countries
China
Contacts
CONTACTWeili Zhao
CONTACTPengpeng Xu
Outcome results
None listed